Faster Relief for Depression Starts with Spravato® in About:blank, Michigan
At LifeStance Health, we provide compassionate care and deep clinical expertise in Spravato® (esketamine) treatment for adults living with treatment-resistant depression (TRD) and major depressive disorder (MDD). Spravato® treatment is available at multiple LifeStance mental health clinics throughout Michigan, where our multidisciplinary team of psychiatric providers delivers personalized support at every step — from your initial evaluation through each in-office treatment session. If depression hasn’t improved with antidepressants alone, Spravato® may help. Take the first step toward mental well-being and schedule your Spravato® treatment appointment today.
Spravato® Treatments At LifeStance
Find a Spravato® Provider in About:blank, Michigan
Filter Provider Results
Find a Spravato® Treatment Clinic Near You:
Spravato® Treatment is Often Covered by Insurance. We accept multiple Insurances in Michigan
Spravato® Therapy FAQ
Researchers believe Spravato® works to treat depression by targeting the NMDA receptor and glutamate neurotransmitter system in your brain. Scientific studies have illuminated the importance of NMDA/glutamate in modulating mood, behavior, memory, and learning.
Yes. Spravato® was approved by the FDA in 2019. It is under patent until 2024, after which there will likely be generic equivalents on the market.
No. Spravato® should be taken in conjunction with an oral antidepressant. Insurance companies require a patient to be prescribed an oral antidepressant prior to approving treatment coverage. Spravato® is intended to supplement but not replace your current anti-depression treatment.
Research studies show an efficacy of 33-60% depending on the duration of treatment.
Addiction to or physical dependence on Spravato® was not found in over 1700 patients included in clinical trials. It is unlikely that Spravato® taken at the doses and frequency used to treat mood symptoms will lead to any dependence or addiction.
Yes. The efficacy of Spravato® has been evaluated in short-term clinical trials and one longer-term maintenance-of-effect trial. In one of the short-term studies, Spravato® demonstrated a statistically significant effect on the severity of depression. In the maintenance trial, patients who continued treatment with Spravato® plus an oral antidepressant experienced a statistically significant longer time to relapse of depressive symptoms.
In a clinical trial for Spravato®, 65% of patients responded to treatment, achieving a 50% or greater reduction in depressive symptoms and 32% were in remission, these patients did not meet criteria for depression. In addition, patients who had responded to Spravato® were 71% less likely to relapse if they continued the medication and if they had been in remission, they were 51% less likely to relapse.